FP09.03 Phase II Randomized Trial to Evaluate Prednisone Taper With or Without Nintedanib for the Treatment of Radiation Pneumonitis

Abstract

Radiation pneumonitis (RP) is the most common limiting toxicity for definitive thoracic radiation therapy. Currently, the only standard management consists of an empiric prolonged steroid taper. Nevertheless, many patients with RP experience subsequent pulmonary exacerbations and worsening lung function leading to significant decline in quality of life. Nintedanib, a multiple tyrosine kinase inhibitor, has been shown to be effective in the treatment of idiopathic pulmonary fibrosis that shares many pathophysiological pathways with the chronic inflammation of the subacute phase of RP.